RxDoctor Payments Data

Edwin Czovek

Physician Assistant · Zephyrhills, FLNPI 1891867396

Payments from drug & device makers

$2,526in general payments, 2019–2025

Across 131 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$533
  • Corium, LLC$445
  • Otsuka America Pharmaceutical, Inc.$315
  • Tris Pharma Inc$171
  • Takeda Pharmaceuticals U.S.A., Inc.$154
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
  • plus $756 from 13 others

What the payments were for

  • Food & beverage$2,526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,526 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$28,100
Medicare patients
83
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl27$40,737
RexultiBrexpiprazole23$34,461
TrintellixVortioxetine Hydrobromide20$16,563
BelsomraSuvorexant12$5,435
Aripiprazole51$3,565
Hydroxyzine Hcl150$3,071
Quetiapine Fumarate ErQuetiapine Fumarate11$2,463
Vilazodone Hcl15$2,371
Mirtazapine101$2,341
Bupropion XlBupropion Hcl76$2,086
Fluvoxamine Maleate39$2,012
Lurasidone Hcl13$1,997
Duloxetine Hcl71$1,962
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$1,570
Trazodone Hcl138$1,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$533$40,73727 claims
Otsuka America Pharmaceutical, Inc.Rexulti$315$34,46123 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$154$16,56320 claims
Almatica Pharma LLCSertraline Hcl$46$945126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →